Two long-lasting human monoclonal antibodies cross-react with monkeypox virus A35 antigen.

[1]  X. Chuai,et al.  Monkeypox virus: a re-emergent threat to humans , 2022, Virologica Sinica.

[2]  D. Sobral,et al.  Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus , 2022, Nature Medicine.

[3]  Y. Xiang,et al.  Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters , 2022, Emerging microbes & infections.

[4]  F. Lienert,et al.  The changing epidemiology of human monkeypox—A potential threat? A systematic review , 2021, medRxiv.

[5]  S. Ovchinnikov,et al.  ColabFold: making protein folding accessible to all , 2022, Nature Methods.

[6]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[7]  Y. Nakazawa,et al.  Monkeypox re-emergence in Africa: a call to expand the concept and practice of One Health , 2019, Expert review of anti-infective therapy.

[8]  R. Eisenberg,et al.  Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections , 2016, Cell.

[9]  Luis Villarreal,et al.  Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination 1 , 2003, The Journal of Immunology.

[10]  S. Hansen,et al.  Duration of antiviral immunity after smallpox vaccination , 2003, Nature Medicine.

[11]  E. A. Uvarova,et al.  Analysis of the Monkeypox Virus Genome , 2002, Virology.

[12]  P E Fine,et al.  The transmission potential of monkeypox virus in human populations. , 1988, International journal of epidemiology.